---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-002960"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-15T00:10:46.114644+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BioCryst licenses navenibart to Neopharmed Gentili in Europe for $70M upfront plus milestones

## Summary
- BioCryst receives $70M upfront and up to $275M in regulatory/sales milestones from Neopharmed Gentili affiliate.
- Tiered royalties on net sales of navenibart in Europe range from 18% to 30%.
- Navenibart Phase 3 in hereditary angioedema on track for US regulatory filing by end of 2027.
- Agreement builds on prior 2025 deal for sale of European ORLADEYO business to Neopharmed Gentili.

## SEC filing metadata
- accession: 0001171843-26-002960
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184326002960/0001171843-26-002960-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184326002960/f8k_050426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-002960
- JSON: https://secwatch.observer/filing/0001171843-26-002960.json
- Plain text: https://secwatch.observer/filing/0001171843-26-002960.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.